Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Genmab A/S - American Depositary Shares (NQ:GMAB)

33.95 +0.32 (+0.95%)
Streaming Delayed Price Updated: 9:52 AM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Genmab A/S - American Depositary Shares

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Stocks That Hit 52-Week Highs On Friday ↗
Before 10 a.m. ET on Friday, 52 companies hit new 52-week highs. Highlights: Microsoft (NASDAQ:MSFT) was the biggest company by market cap to set a new 52-week high... 
Via Benzinga
News headline image
Genmab Stock Flashes Healthy RS Rating ↗
Genmab stock just cleared an important benchmark with an RS Rating upgrade from 79 to 82. Is Genmab on your watchlist? 
Via Investor's Business Daily
News headline image
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
News headline image
Genmab A/S (GMAB) Q2 2021 Earnings Call Transcript ↗
GMAB earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
2 Biotech Stocks to Buy for Outsized Gains ↗
Biotech companies’ success in responding to the COVID-19 pandemic by rapidly developing COVID-19 medicines and vaccines exemplified the sector’s importance and garnered significant investor attention. 
Via Talk Markets
News headline image
The Daily Biotech Pulse: Biogen Faces Another Clinical Setback, CureVac's COVID-19 Vaccine Study Fails, Moment Of Reckoning For Orphazyme ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 16) Alexion Pharmaceuticals,... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Merck Completes Organon Spin-Off, Auris Repositions As RNA Therapeutic Company With Trasir Purchase, Replimune's Readout ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 2) BioCryst Pharmaceuticals,... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
News headline image
Genmab and Bolt Biotherapeutics Announce Oncology Research and Development Collaboration
From Genmab A/S
Via Business Wire
News headline image
Genmab - Janssen's Darzalex Wins Positive Opinion In Europe For Two New Indications ↗
Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion and recommended granting marketing authorization to ... 
Via Benzinga
News headline image
Genmab A/S (GMAB) Q1 2021 Earnings Call Transcript ↗
GMAB earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer
From Genmab A/S
Via Business Wire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.